Vaccines Procurement Intelligence Is Expected to Exhibit CAGR Of 4.7% During 2023-2030Posted by rahul nikade on July 2nd, 2024 Vaccines Procurement Intelligence The vaccines category is anticipated to grow at a CAGR of 4.7% from 2023 to 2030. They can be classified mainly into six types - Live-attenuated, inactivated, sub-unit, toxoid, viral vector, and messenger RNA (mRNA) vaccines. Among these, the mRNA sector held the largest share of 39% in 2022. The growth of the category is mainly attributed to the rising requirement for effective immunization, increasing R&D investments coupled with technological advancements, and a wider accessibility of the product especially in lower-income countries. In recent times, the emergence of new COVID variants and other infectious diseases such as “Disease X”, Nipah virus, Ebola, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever (RVF), etc. are further boosting the product demand. Order your copy of the Vaccines category procurement intelligence report 2023-2030, published by Grand View Research, to get more details regarding day one, quick wins, portfolio analysis, key negotiation strategies of key suppliers, and low-cost/best-cost sourcing analysis Vaccines Procurement Intelligence Report Scope The Vaccines category is expected to have pricing growth outlook of 6% - 10% (Annually) from 2023 to 2030, with below pricing models.
Supplier Selection Scope of Report
Supplier selection criteria of Report
Vaccines Procurement Intelligence Report Coverage Grand View Research will cover the following aspects in the report:
Vaccines Procurement Cost and Supplier Intelligence Cost modelling is an effective method that may be used to simulate bottlenecks, improve production efficiency, and get a deeper understanding of the processes involved in making vaccines. From research to GMP manufacturing stages, different types of direct and indirect costs are involved in the process. The main key cost components associated with manufacturing are capital, labor, materials, consumables, and other costs. Capital costs can include components such as equipment, capital estimates (such as installation, pipework, HVAC, power, and building), and validation. Capital costs are the largest component in the process accounting for between 41 - 49% of the total cost structure. Consumables can include filters, membranes, single-use components, etc. Other costs can include R&D, marketing and licensing, packaging, distribution, and engineering, which can vary based on the specifications and technology of the individual product. According to Biopharm Services’ study, it was also found that the cost per dose is higher for stainless steel equipment. This is mainly attributed to factors such as higher capital and labor contribution compared to consumables and materials. For instance, in the case of inactivated vaccines, a facility with a lower utilization rate, using stainless steel processes, the capital charge and labor accounted for 48% and 14% respectively. Whereas, under the same conditions, in a facility using single-use processes, the capital and labor costs accounted for 41% and 9% respectively. In March 2023, the prices for Moderna's COVID-19 vaccine were around USD 130 per dose. In September 2023, most of the manufacturers priced their COVID-19 vaccine shots between USD 120 - 130 per dose. List of Key Suppliers
Add-on Services provided by Grand View Research Pipeline:
Component wise cost break down for better negotiation for the client, highlights the key cost drivers in the market with future price fluctuation for different materials (e.g.: steel, aluminum, etc.) used in the production process
Offering cost transparency for different products / services procured by the client. A typical report involves 2-3 case scenarios helping clients to select the best suited engagement with the supplier
Determining and forecasting salaries for specific skill set labor to make decision on outsourcing vs in-house.
A typical newsletter study by capturing latest information for specific suppliers related to: M&As, technological innovations, expansion, litigations, bankruptcy etc. Browse through Grand View Research’s collection of procurement intelligence studies:
Brief about Pipeline by Grand View Research: A smart and effective supply chain is essential for growth in any organization. Pipeline division at Grand View Research provides detailed insights on every aspect of supply chain, which helps in efficient procurement decisions. Our services include (not limited to):
Like it? Share it!More by this author |